Evidence map›Paper›PMID 30976430›Full record

ArticleNew microbes and new infections2019

NDM-1 carbapenemase in

J E Villacís, M Bovera, D Romero-Alvarez, F Cornejo, V Albán, G Trueba, H F Dorn, J A Reyes

Open access · goldAbstract read
In one paragraph

Article in New microbes and new infections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Carbapenem Resistance inBioMed research international · 2024
    Article
  3. Genomic study ofFrontiers in microbiology · 2024
    Article
  4. Article
  5. Article
  6. Detection of NDM-1-PositiveInfection and drug resistance · 2022
    Article
  7. Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

J E VillacísCarrera de Bioquímica Clínica, Facultad de Medicina, Pontificia Universidad Católica del Ecuador, Quito, Ecuador.
M BoveraHospital de los Valles, Quito, Ecuador.
D Romero-AlvarezDepartment of Ecology & Evolutionary Biology and Biodiversity Institute, University of Kansas, Lawrence, KS, USA.
F CornejoHospital de los Valles, Quito, Ecuador.
V AlbánInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco, Quito, Pichincha, Ecuador.
G TruebaInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco, Quito, Pichincha, Ecuador.
H F DornHospital de los Valles, Quito, Ecuador.
J A ReyesFacultad de Ciencias Químicas, Universidad Central del Ecuador, Quito, Pichincha, Ecuador.
Hospital Vozandes · ECUniversidad San Francisco de Quito · ECCentral University of Ecuador · ECPontificia Universidad Católica del Ecuador · ECUniversity of Kansas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe a clinical case of

methodsWe used multilocus sequence typing (MLST) to confirm the bacterial species and the sequence type of an

resultsMolecular characterization revealed the presence of

conclusionsTo the best of our knowledge, this is the first report of

Indexed as

Acinetobacter baumanniiantibiotic resistanceblaNDM-1MSLTsequence type 32

Identifiers

PMID30976430
PMCPMC6438911
OpenAlexW2922317491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.